TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo October 15, 2020 Marc Hedrick, MD President and Chief Executive Officer Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 Filed October 3, 2020 File No. 333-249410 Dear Mr. Hedrick: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew L. Strong